Del-Budai Centrumkorhaz Szent Imre Egyetemi Oktatokorhaz
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The centre is investigating novel strategies to improve cardiovascular risk management, focusing on blood‑pressure control and cholesterol reduction for patients with elevated heart‑related danger.
- Hyperlipidaemia
- Resistant hypertension
- Uncontrolled hypertension
- Acute heart failure
With 11 dedicated investigators, the site supports 14 active studies and contributes to Hungary’s growing clinical‑research landscape from its Budapest location.
Digestive System Diseases
Researchers are assessing the long‑term safety and therapeutic benefit of emerging agents for patients with severe intestinal insufficiency, aiming to enhance nutrition absorption and quality of life.
- Short Bowel Syndrome
- Venous thromboembolism in gastrointestinal cancer
The Endocrinology and Metabolic Centre collaborates with local hospitals to enroll participants and generate data that may reshape treatment standards for complex digestive conditions.
Immune System Diseases
The department is testing a targeted immunomodulator to reduce inflammation and maintain remission in a rare vasculitis, offering hope for patients who face vision loss and severe pain.
- Giant Cell Arteritis
This work reflects the site’s commitment to advancing therapies for autoimmune disorders through rigorous safety and efficacy evaluation.
Neoplasms
Ongoing trials evaluate cutting‑edge biologics and antibody‑drug conjugates designed to halt tumor growth and prolong survival in several aggressive cancers.
- HER2‑positive metastatic breast cancer
- Hormone‑receptor‑positive HER2‑negative advanced breast cancer
- Resectable cutaneous squamous cell carcinoma
- General breast cancer
By integrating immunotherapy and targeted agents, the site seeks to expand therapeutic options for patients confronting life‑threatening tumors.
Nervous System Diseases
A combination regimen is being examined for its ability to alleviate painful symptoms and improve nerve function in individuals with diabetes‑related nerve damage.
- Diabetic sensorimotor polyneuropathy
The study underscores the centre’s focus on neuro‑metabolic complications that significantly impact daily living.
Nutritional and Metabolic Diseases
Clinical investigations target metabolic imbalances, aiming to lower harmful lipids and support patients with chronic nutrient‑absorption challenges.
- Hyperlipidaemia
- Metabolic complications of short bowel syndrome
Through these trials, the Budapest facility contributes valuable insights into managing disorders that affect the body’s energy and nutrient pathways.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Del-Budai Centrumkorhaz Szent Imre Egyetemi Oktatokorhaz
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF) | Zealand Pharma A/S | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 2 | Unknown | 2022-08-10 | 2022-09-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.